Jagsonpal Pharmaceuticals logo

Jagsonpal Pharmaceuticals

JAGSNPHARM NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹1,523 Cr
Volatility
Moderate
P/E Ratio
34.05
EBITDA
₹56.00 Cr
Return on Equity
23.07%
Debt to Equity
0.03
Book Value
₹41.84
EPS
₹8.61
52W High
₹264.5
52W Low
₹155

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

4
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 50.3%
  • Promoter holding has increased by 1.17% over last quarter.
  • Company's working capital requirements have reduced from 24.0 days to 11.0 days

Weaknesses

1
  • The company has delivered a poor sales growth of 8.85% over past five years.

Growth Rate

Revenue Growth
3.73% lower than 3Y
Net Income Growth
-19.98% lower than 3Y
Cash Flow Change
57.24% higher than 3Y
ROE
92.41% higher than 3Y
ROCE
81.03% higher than 3Y
EBITDA Margin (Avg.)
-12.57% lower than 3Y

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
60
58
47
43
61
75
74
59
76
74
73
64
82
Expenses
52
49
44
41
51
58
58
50
61
58
57
53
65
Operating Profit
9
8
3
3
10
16
16
9
14
16
16
11
17
OPM %
14%
14%
7%
6%
17%
22%
21%
15%
19%
22%
22%
17%
21%
Other Income
2
2
3
2
-2
2
26
3
3
3
1
3
3
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
1
2
2
2
2
2
2
2
2
PBT
10
10
5
5
7
15
39
9
14
17
15
12
18
Tax %
26%
25%
25%
22%
25%
25%
17%
24%
25%
25%
25%
25%
25%
Net Profit
7
7
4
4
5
11
32
7
11
13
11
9
13
EPS in Rs
1.14
1.14
0.6
0.54
0.81
1.73
4.82
0.99
1.62
1.89
1.64
1.31
2
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
138
143
144
127
167
159
188
218
237
209
269
287
294
Expenses
129
132
138
138
157
150
169
192
203
186
218
229
233
Operating Profit
9
12
6
-11
9
9
19
26
34
23
51
58
61
OPM %
6%
8%
4%
-9%
6%
5%
10%
12%
14%
11%
19%
20%
21%
Other Income
0
1
13
0
1
3
4
3
2
9
28
10
10
Interest
4
5
3
1
1
1
1
0
0
1
1
1
1
Depreciation
3
3
2
0
1
1
1
2
1
2
8
9
9
PBT
2
4
14
-12
9
9
22
27
35
30
70
58
61
Tax %
30%
20%
18%
-1%
20%
16%
22%
29%
23%
25%
21%
25%
—
Net Profit
1
3
12
-12
7
8
17
19
27
22
55
43
45
EPS in Rs
0.18
0.5
1.81
-1.76
1.1
1.2
2.6
2.88
4.08
3.4
8.34
6.43
6.84
Div. Payout %
22%
8%
2%
-2%
9%
17%
15%
56%
49%
59%
30%
62%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
13
13
13
13
13
13
13
13
13
13
13
13
Reserves
82
85
97
85
91
98
109
120
146
174
227
263
Borrowings
39
38
8
8
4
5
7
0
6
9
9
8
Other Liabilities
19
22
25
23
28
31
35
31
30
21
29
32
Total Liabilities
154
159
143
130
136
147
164
164
195
217
278
317
Fixed Assets
52
52
22
21
22
22
26
23
24
9
94
85
CWIP
0
0
0
3
4
4
0
0
0
0
0
0
Investments
0
0
0
0
0
11
15
51
1
0
0
0
Other Assets
102
108
121
105
110
109
123
91
170
208
184
231
Total Assets
154
159
143
130
136
147
164
164
195
217
278
317
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
4
9
-3
-2
31
11
28
7
47
35
55
47
Investing
0
-2
41
-3
-1
-11
-2
-26
-58
-25
-45
-36
Financing
-1
-6
-34
-1
-6
-1
-7
-18
0
-9
-12
-12
Net Cash Flow
2
1
5
-6
24
0
19
-36
-11
2
-2
-1
Free Cash Flow
4
6
40
-5
30
12
28
6
48
35
90
47
CFO/OP
53
83
-6
14
311
150
164
54
158
189
124
101
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
119
106
100
73
45
49
25
26
32
19
18
22
Inventory Days
176
246
295
307
164
191
134
122
82
68
58
51
Days Payable
42
60
56
54
59
76
82
76
66
35
37
40
Cash Conversion Cycle
252
292
339
325
150
164
77
72
48
53
39
33
Working Capital Days
68
72
154
149
67
55
32
59
34
52
9
11
ROCE %
5%
7%
3%
-10%
9%
9%
18%
20%
25%
17%
23%
23%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Jagsonpal Pharmaceuticals insights

66 extracted metrics + investor summaries across FY08–FY27.

Log in — free

Shareholding Pattern

DIIs0.62%Promot.69.05%FIIs2.30%Others8.70%Public19.33%As ofJun 2026

Documents

Frequently Asked Questions about Jagsonpal Pharmaceuticals

What does Jagsonpal Pharmaceuticals Ltd do?
Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients[1]
Where is Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) listed?
Jagsonpal Pharmaceuticals Ltd trades as JAGSNPHARM on the NSE and under code 507789 on the BSE.
Which sector does Jagsonpal Pharmaceuticals Ltd belong to?
Jagsonpal Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Jagsonpal Pharmaceuticals Ltd?
Jagsonpal Pharmaceuticals Ltd has a market capitalisation of ₹1,523 Cr, which places it in the Small Cap band.
What is the PE ratio of Jagsonpal Pharmaceuticals Ltd?
Jagsonpal Pharmaceuticals Ltd trades at a PE ratio of 34.05, on earnings per share of ₹8.61, against a book value of ₹41.84 per share.
What is the 52-week high and low of Jagsonpal Pharmaceuticals Ltd?
Over the last 52 weeks Jagsonpal Pharmaceuticals Ltd has traded between ₹155 and ₹264.5.
Does Jagsonpal Pharmaceuticals Ltd pay dividends?
Jagsonpal Pharmaceuticals Ltd has a dividend yield of 1.72%.
What is the Return on Equity (ROE) of Jagsonpal Pharmaceuticals Ltd?
Jagsonpal Pharmaceuticals Ltd reported a return on equity of 23.07%. Its debt-to-equity ratio is 0.03.

Company Information

Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients[1]

Website jagsonpal.com
CEO Mr. Manish Gupta
Employees 1,399
Listed 2000-03-01
Face Value ₹ 2
Issued Size 6,67,81,270

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/JAGSNPHARM.md for Jagsonpal Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List